146 related articles for article (PubMed ID: 28070733)
21. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
22. Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study.
Saunders WB; Nguyen H; Kalsekar I
Diabetes Metab Syndr Obes; 2016; 9():217-23. PubMed ID: 27486339
[TBL] [Abstract][Full Text] [Related]
23. Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin.
Blonde L; Raccah D; Lew E; Meyers J; Nikonova E; Ajmera M; Davis KL; Bertolini M; Guerci B
Diabetes Ther; 2018 Jun; 9(3):1169-1184. PubMed ID: 29675797
[TBL] [Abstract][Full Text] [Related]
24. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella R; Pechtner V; Corcos A; Consoli A
Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
[TBL] [Abstract][Full Text] [Related]
25. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
Gæde P; Johansen P; Tikkanen CK; Pollock RF; Hunt B; Malkin SJP
Diabetes Ther; 2019 Aug; 10(4):1297-1317. PubMed ID: 31098942
[TBL] [Abstract][Full Text] [Related]
26. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
Meece J
Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986
[TBL] [Abstract][Full Text] [Related]
27. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
28. Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies.
McDonell AL; Kiiskinen U; Zammit DC; Kotchie RW; Thuresson PO; Nicolay C; Haslam T; Bruinsma M; Janszen-Van Oosterhout AJ; Otto T
Clinicoecon Outcomes Res; 2015; 7():95-103. PubMed ID: 25674008
[TBL] [Abstract][Full Text] [Related]
29. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
Guyton J; Jeon M; Brooks A
Am J Health Syst Pharm; 2019 Oct; 76(21):1739-1748. PubMed ID: 31612934
[TBL] [Abstract][Full Text] [Related]
30. Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom.
Hunt B; Ye Q; Valentine WJ; Ashley D
Diabetes Ther; 2017 Feb; 8(1):129-147. PubMed ID: 28058656
[TBL] [Abstract][Full Text] [Related]
31. Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany.
Qiao Q; Ouwens MJ; Grandy S; Johnsson K; Kostev K
Diabetes Metab Syndr Obes; 2016; 9():201-5. PubMed ID: 27418849
[TBL] [Abstract][Full Text] [Related]
32. Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg.
Malmenäs M; Bouchard JR; Langer J
Clin Ther; 2013 Jun; 35(6):795-807. PubMed ID: 23642290
[TBL] [Abstract][Full Text] [Related]
33. A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss.
Pereira MJ; Lundkvist P; Kamble PG; Lau J; Martins JG; Sjöström CD; Schnecke V; Walentinsson A; Johnsson E; Eriksson JW
Diabetes Ther; 2018 Aug; 9(4):1511-1532. PubMed ID: 29949016
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review.
Aroda VR; Henry RR; Han J; Huang W; DeYoung MB; Darsow T; Hoogwerf BJ
Clin Ther; 2012 Jun; 34(6):1247-1258.e22. PubMed ID: 22608780
[TBL] [Abstract][Full Text] [Related]
35. Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study.
Lingvay I; Kirk AR; Lophaven S; Wolden ML; Shubrook JH
Diabetes Ther; 2021 Mar; 12(3):879-896. PubMed ID: 33594582
[TBL] [Abstract][Full Text] [Related]
36. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
37. The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France.
Basson M; Ntais D; Ayyub R; Wright D; Lowin J; Chartier F; Roze S; Norrbacka K
Diabetes Ther; 2018 Feb; 9(1):13-25. PubMed ID: 29134607
[TBL] [Abstract][Full Text] [Related]
38. Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes.
Ross SA; Ballantine J
Curr Med Res Opin; 2013 Dec; 29(12):1617-26. PubMed ID: 23971789
[TBL] [Abstract][Full Text] [Related]
39. Clinical pharmacology of glucagon-like peptide-1 receptor agonists.
Sfairopoulos D; Liatis S; Tigas S; Liberopoulos E
Hormones (Athens); 2018 Sep; 17(3):333-350. PubMed ID: 29949126
[TBL] [Abstract][Full Text] [Related]
40. Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists.
Uccellatore A; Genovese S; Dicembrini I; Mannucci E; Ceriello A
Diabetes Ther; 2015 Sep; 6(3):239-56. PubMed ID: 26271795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]